Centre Asset Management LLC boosted its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 5.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 29,482 shares of the company’s stock after purchasing an additional 1,581 shares during the quarter. Centre Asset Management LLC’s holdings in Johnson & Johnson were worth $5,208,000 at the end of the most recent quarter.
Other institutional investors have also added to or reduced their stakes in the company. Glassy Mountain Advisors Inc. purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth $35,000. Retirement Financial Solutions LLC purchased a new stake in Johnson & Johnson during the 4th quarter valued at about $40,000. TD Capital Management LLC bought a new stake in Johnson & Johnson during the 3rd quarter valued at about $48,000. VitalStone Financial LLC purchased a new position in Johnson & Johnson in the fourth quarter worth about $52,000. Finally, Iron Horse Wealth Management LLC lifted its stake in shares of Johnson & Johnson by 112.8% in the fourth quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock worth $53,000 after buying an additional 159 shares in the last quarter. Institutional investors own 67.94% of the company’s stock.
Analyst Ratings Changes
Several brokerages have recently issued reports on JNJ. Credit Suisse Group upped their target price on shares of Johnson & Johnson from $168.00 to $170.00 in a research note on Friday. StockNews.com started coverage on Johnson & Johnson in a research note on Thursday, March 16th. They issued a “strong-buy” rating for the company. Guggenheim assumed coverage on Johnson & Johnson in a research note on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price target for the company. Raymond James reduced their price target on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a research note on Wednesday, April 19th. Finally, UBS Group assumed coverage on shares of Johnson & Johnson in a research note on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 price target for the company. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $173.00.
Insider Activity at Johnson & Johnson
Johnson & Johnson Trading Up 0.3 %
NYSE:JNJ opened at $162.68 on Monday. The business has a fifty day moving average price of $158.33 and a 200-day moving average price of $166.98. The firm has a market capitalization of $422.76 billion, a price-to-earnings ratio of 34.03, a price-to-earnings-growth ratio of 2.77 and a beta of 0.53. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.07 and a quick ratio of 0.77. Johnson & Johnson has a one year low of $150.11 and a one year high of $183.35.
Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.51 by $0.17. The company had revenue of $24.75 billion during the quarter, compared to the consensus estimate of $23.61 billion. Johnson & Johnson had a return on equity of 36.13% and a net margin of 13.22%. The firm’s revenue was up 5.6% on a year-over-year basis. During the same period in the previous year, the company posted $2.67 EPS. Sell-side analysts forecast that Johnson & Johnson will post 10.66 EPS for the current year.
Johnson & Johnson Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be paid a dividend of $1.19 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date is Monday, May 22nd. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.93%. Johnson & Johnson’s payout ratio is 94.56%.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Articles
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- MarketBeat Week in Review – 5/1 – 5/5
- It’s Time To Check Into Booking.Com
- Shopify Delivers Growth And Efficiency; Shares Surge
- Advanced Micro Devices Bullish Reversal Is Still In Play
- Broadcom Shares Trade In Tight Range Ahead Of Q2 Earnings Report
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
